These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17639646)

  • 1. Health services for HIV/AIDS, HCV, and sexually transmitted infections in substance abuse treatment programs.
    Brown LS; Kritz S; Goldsmith RJ; Bini EJ; Robinson J; Alderson D; Rotrosen J
    Public Health Rep; 2007; 122(4):441-51. PubMed ID: 17639646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to providing health services for HIV/AIDS, hepatitis C virus infection and sexually transmitted infections in substance abuse treatment programs in the United States.
    Bini EJ; Kritz S; Brown LS; Robinson J; Alderson D; Rotrosen J
    J Addict Dis; 2011 Apr; 30(2):98-109. PubMed ID: 21491291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of substance abuse treatment programs providing services for HIV/AIDS, hepatitis C virus infection, and sexually transmitted infections: the National Drug Abuse Treatment Clinical Trials Network.
    Brown LS; Kritz SA; Goldsmith RJ; Bini EJ; Rotrosen J; Baker S; Robinson J; McAuliffe P
    J Subst Abuse Treat; 2006 Jun; 30(4):315-21. PubMed ID: 16716846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. States and substance abuse treatment programs: funding and guidelines for infection-related services.
    Kritz S; Brown LS; Goldsmith RJ; Bini EJ; Robinson J; Alderson D; Novo P; Rotrosen J
    Am J Public Health; 2008 May; 98(5):824-6. PubMed ID: 18381995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.
    Bini EJ; Kritz S; Brown LS; Robinson J; Calsyn D; Alderson D; Tracy K; McAuliffe P; Smith C; Rotrosen J
    J Subst Abuse Treat; 2012 Jun; 42(4):438-45. PubMed ID: 22035702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disparities in Health Services for HIV/AIDS, Hepatitis C Virus, and Sexually Transmitted Infections: Role of Substance Abuse Treatment Programs.
    Brown LS; Kritz S; Muhammad A; Bini EJ; Goldsmith RJ; Robinson J; Alderson D; Hasin DS; Rotrosen J
    J Addict Med; 2009 Jun; 3(2):95-102. PubMed ID: 20161081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National survey of HIV and hepatitis testing and vaccination services provided by drug and alcohol agencies in Australia.
    Winstock AR; Anderson CM; Sheridan J
    Med J Aust; 2006 Jun; 184(11):560-2. PubMed ID: 16768662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program.
    Gunn RA; Lee MA; Callahan DB; Gonzales P; Murray PJ; Margolis HS
    Am J Prev Med; 2005 Jul; 29(1):27-33. PubMed ID: 15958248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to enrollment in drug abuse treatment and suggestions for reducing them: opinions of drug injecting street outreach clients and other system stakeholders.
    Appel PW; Ellison AA; Jansky HK; Oldak R
    Am J Drug Alcohol Abuse; 2004; 30(1):129-53. PubMed ID: 15083558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States.
    Frimpong JA; D'Aunno T; Helleringer S; Metsch LR
    BMC Public Health; 2016 Jul; 16():666. PubMed ID: 27473519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in testing for human immunodeficiency virus, sexually transmitted infections, and hepatitis C virus in opioid treatment programs.
    Bachhuber MA; Cunningham CO
    JAMA; 2013 Dec; 310(24):2671-2. PubMed ID: 24368468
    [No Abstract]   [Full Text] [Related]  

  • 13. Organizational factors related to AIDS/HIV education in outpatient substance abuse treatment units.
    Clapp JD
    J Health Soc Policy; 1998; 9(3):1-13. PubMed ID: 10174381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substance abuse treatment as HIV prevention: more questions than answers.
    Brown LS; Kritz S; Bini EJ; Louie B; Robinson J; Alderson D; Rotrosen J
    J Natl Med Assoc; 2010 Dec; 102(12):1183-91. PubMed ID: 21287899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urgent need for HIV and hepatitis prevention in drug treatment programs in Hungary.
    Gyarmathy VA; Rácz J; Neaigus A; Ujhelyi E
    AIDS Educ Prev; 2004 Jun; 16(3):276-87. PubMed ID: 15237056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance abuse treatment clinician opinions and infectious disease service delivery.
    Tracy K; Brown LS; Kritz S; Alderson D; Robinson J; Bini EJ; Levy M; Calsyn D; Rieckmann T; Fuller B; McAuliffe P; Rotrosen J
    J Addict Dis; 2009; 28(1):8-12. PubMed ID: 19197590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017.
    Parcesepe AM; Lancaster K; Edelman EJ; DeBoni R; Ross J; Atwoli L; Tlali M; Althoff K; Tine J; Duda SN; Wester CW; Nash D;
    PLoS One; 2020; 15(8):e0237772. PubMed ID: 32853246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leveraging Health Department Capacities, Partnerships, and Health Insurance for Infectious Disease Response in Massachusetts, 2014-2018.
    Fukuda HD; Randall LM; Meehan T; Cranston K
    Public Health Rep; 2020; 135(1_suppl):75S-81S. PubMed ID: 32735184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial.
    Frimpong JA; D'Aunno T; Perlman DC; Strauss SM; Mallow A; Hernandez D; Schackman BR; Feaster DJ; Metsch LR
    Trials; 2016 Mar; 17(1):117. PubMed ID: 26936623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV/AIDS services in private substance abuse treatment programs.
    Abraham AJ; O'Brien LA; Bride BE; Roman PM
    Drug Alcohol Depend; 2011 May; 115(1-2):16-22. PubMed ID: 21145179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.